Genomic and Transcriptomic Profiling of Patients with Malignant Pleural and Peritoneal Mesothelioma: The NCI Cohort

Malignant mesothelioma is an aggressive cancer with limited treatment options and poor prognosis. Better understanding of mesothelioma genomics and transcriptomics could advance novel therapies. We performed whole-exome sequencing (WXS) of germline and tumors of 122 patients, and RNA-sequencing (RNA-Seq) of tumor samples of 100 patients with pleural, peritoneal, and tunica-vaginalis mesothelioma.The biospecimens used in this study were collected as a part of the Mesothelioma Natural History Protocol (https://clinicaltrials.gov/ct2/show/NCT01950572), wherein, samples were collected from subjects with malignant mesothelioma as listed in the eligibility criteria below and written consent from each participant was obtained before sample acquisition. ]]>
Inclusion Criteria All patients ≥ 2 years of age with malignant mesothelioma All patients ≥ 18 years of age with thymic carcinoma, pancreatic or biliary adenocarcinoma, or lung, gastric or ovarian cancersConfirmed pathological diagnosis is required. Subjects who are able and willing to provide informed consent to participation.All patients, who are screened for treatment protocols involving mesothelin targeted therapies, will be screened for this protocol. Patients with the above malignancies, who are evaluated for a second opinion, will also be recruited.Exclusion Criteria Active symptomatic major organ disorder that would increase the risk of biopsy, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, and pulmonary dysfunction. Pregnant or breast feeding women will not be eligible for this protocol. Active concomitant medical or psychological illnesses that may increase the risk to the subject, or in adult patients' inability to obtain informed consent, at the discretion of the principal investigator. ]]>
Opened 9/2013 - currently enrolling]]>